Hi Paul,
While immuno is one of my weak points, I'd have to echo Allen's question. I
wouldn't think that immunophenotype percentages would change. If you
looked at proliferation antigens (p53, c-myc, Ki-67) then I would expect
increased expression with activation.
Good luck,
Steve
>In article <33id2j$drg at mercury.hgmp.mrc.ac.uk>, p-donoho at nimr.mrc.ac.uk (
Paul>M. Donohoe) writes:
>> I am examining the changes in immune system parameters over a time
>>course in rats with Adjuvant Arthritis, and in r65kD-protected rats,>> one
part of which is looking at lymphocyte surface markers by>> immunostaining
and FACS. All the antibodies I've used are commercial,>> and all give
nice, discrete populations, with the correct levels of>> expression. I
have used MAbs against CD2, CD3, CD4, CD5, CD8, CD25>> (IL2R), CD44, CD45RC,
ab-TCR and RT1B (MHC class II).>> However, during the disease when there is
a high level of inflammation,>> and in the protected groups, also presumably
immunologically active,>> there is NO DIFFERENCE AT ALL in the levels of any
of these markers,>> either by percentage of population, or mean intensity of
--snipped to save space--
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Steve G. Hilliard : hilliard at zookeeper.zoo.uga.edu
Cell Analysis Facility :
University of Georgia : "Be good and you will be lonesome..."
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
